Media

Media enquiries can also be emailed to mediaenquiriesUK@ipsen.com. Please note that we are unable to respond to any non-media enquiries sent to this address.

_{Audience: General public}
_{ALL-UK-000825}
_{Date of preparation: April 2019}

7 results

February 9, 2021

Ipsen and Mendelian Announce Landmark Partnership to Reshape Rare Disease Diagnosis using Pioneering MendelScan Technology

Press Releases

January 6, 2020

Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy

Press Releases

July 30, 2019

Ipsen UK & Ireland Launches New Pre-filled Syringe for Somatuline® Autogel® (lanreotide)

Press Releases

June 4, 2019

Dysport® (clostridium botulinum type a toxin-haemagglutinin complex) becomes first and only botulinum toxin type A to be granted a licence update for administration by healthcare professionals, such as physiotherapists, in the UK

Press Releases

January 17, 2019

Scotland first in UK to make Cabometyx®▼(cabozantinib) routinely available for individuals living with advanced kidney cancer1

Press Releases

January 17, 2019

Life-extending tablet for advanced kidney cancer, Cabometyx®▼(cabozantinib), approved by NICE for routine access by English and Welsh patients1

Press Releases

September 3, 2018

Ipsen UK & Ireland sets out bold vision with appointment of Asad Mohsin Ali as General Manager

Press Releases

© Ipsen Group 2019